Marketing authorisation has not yet been provided for Fruquintinib for previously treated metastatic colorectal cancer. We are therefore unable to publish the guideline until this is received.
This page was last updated:
Marketing authorisation has not yet been provided for Fruquintinib for previously treated metastatic colorectal cancer. We are therefore unable to publish the guideline until this is received.
This page was last updated: